The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.